Flex reports Phase II data for FLX-787 in MS patients

Flex Pharma Inc. (NASDAQ:FLKS) reported top-line data from a prespecified analysis of the parallel treatment phase of a double-blind, crossover Phase II trial in 57 multiple sclerosis patients with frequent muscle cramps, spasms and spasticity showing that twice-daily 19 mg oral FLX-787 in a liquid formulation significantly reduced the frequency of cramps and spasms by 27.3% from baseline to day 14 vs. and increase of 14.2% for placebo (p=0.0017). FLX-787 also significantly increased cramp-free days per 14-day period by 1.4 days vs. 0 days for placebo (p=0.0457).

Flex said FLX-787 did not lead to a significant improvement in the frequency of cramps and spasms vs. placebo in an analysis incorporating both crossover periods...